Show simple item record

dc.contributor.authorKummen, Martin
dc.contributor.authorThingholm, Louise B.
dc.contributor.authorRühlemann, Malte C.
dc.contributor.authorHolm, Kristian
dc.contributor.authorHansen, Simen Hyll
dc.contributor.authorMoitinho-Silva, Lucas
dc.contributor.authorLiwinski, Timur
dc.contributor.authorZenouzi, Roman
dc.contributor.authorLarsen, Christopher Storm
dc.contributor.authorMidttun, Øivind
dc.contributor.authorMcCann, Adrian
dc.contributor.authorUeland, Per Magne
dc.contributor.authorHøivik, Marte Lie
dc.contributor.authorVesterhus, Mette
dc.contributor.authorTrøseid, Marius
dc.contributor.authorLaudes, Matthias
dc.contributor.authorLieb, Wolfgang
dc.contributor.authorKarlsen, Tom Hemming
dc.contributor.authorBang, Corinna
dc.contributor.authorSchramm, Christoph
dc.contributor.authorFranke, Andre
dc.contributor.authorHov, Johannes Espolin Roksund
dc.date.accessioned2021-07-05T12:16:57Z
dc.date.available2021-07-05T12:16:57Z
dc.date.created2021-02-19T08:14:59Z
dc.date.issued2021
dc.identifier.issn0016-5085
dc.identifier.urihttps://hdl.handle.net/11250/2763418
dc.description.abstractBackground & Aims To influence host and disease phenotype, compositional microbiome changes, which have been demonstrated in patients with primary sclerosing cholangitis (PSC), must be accompanied by functional changes. We therefore aimed to characterize the genetic potential of the gut microbiome in patients with PSC compared with healthy controls (HCs) and patients with inflammatory bowel disease (IBD). Methods Fecal DNA from 2 cohorts (1 Norwegian and 1 German), in total comprising 136 patients with PSC (58% with IBD), 158 HCs, and 93 patients with IBD without PSC, were subjected to metagenomic shotgun sequencing, generating 17 billion paired-end sequences, which were processed using HUMAnN2 and MetaPhlAn2, and analyzed using generalized linear models and random effects meta-analyses. Results Patients with PSC had fewer microbial genes compared with HCs (P < .0001). Compared with HCs, patients with PSC showed enrichment and increased prevalence of Clostridium species and a depletion of, for example, Eubacterium spp and Ruminococcus obeum. Patients with PSC showed marked differences in the abundance of genes related to vitamin B6 synthesis and branched-chain amino acid synthesis (Qfdr < .05). Targeted metabolomics of plasma from an independent set of patients with PSC and controls found reduced concentrations of vitamin B6 and branched-chain amino acids in PSC (P < .0001), which strongly associated with reduced liver transplantation–free survival (log-rank P < .001). No taxonomic or functional differences were detected between patients with PSC with and without IBD. Conclusions The gut microbiome in patients with PSC exhibits large functional differences compared with that in HCs, including microbial metabolism of essential nutrients. Alterations in related circulating metabolites associated with disease course, suggesting that microbial functions may be relevant for the disease process in PSC.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleAltered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitisen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2021 by the AGA Instituteen_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.doi10.1053/j.gastro.2020.12.058
dc.identifier.cristin1891587
dc.source.journalGastroenterologyen_US
dc.source.pagenumber1784-1798en_US
dc.identifier.citationGastroenterology. 2021, 160 (5), 1784-1798.en_US
dc.source.volume160en_US
dc.source.issue5en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal